Expert Interviews

With Martina Murphy, MD, the Oncology Brothers discuss the latest advancements in the diagnosis and treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancers, emphasizing the importance of a multidisciplinary approach for optimal patient outcomes.

Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.

Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.

cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.

Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases.

Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.

Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.

Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.

STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.

Panelists discuss key takeaways from the analysis and offer clinical pearls on incorporating prophylactic dexamethasone 8 mg into treatment with amivantamab and lazertinib for community colleagues.

Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.

STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.

Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.

Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.

Panelists discuss how community practices establish protocols and processes for ongoing monitoring and management of potential long-term complications or adverse events from bispecific therapy.